Starling et al., 1986 - Google Patents
Human prostate tissue antigens defined by murine monoclonal antibodiesStarling et al., 1986
View PDF- Document ID
- 17295872983399046690
- Author
- Starling J
- Sieg S
- Beckett M
- Wirth P
- Wahab Z
- Schellhammer P
- Ladaga L
- Poleskic S
- Wright Jr G
- Publication year
- Publication venue
- Cancer research
External Links
Snippet
BALB/c mice were hyperimmunized against a membrane preparation derived from a pool of transurethral resection specimens which included three benign prostatic hyperplasia and one prostate adenocarcinoma tissue samples. The activated lymphocytes were fused with …
- 210000002307 Prostate 0 title abstract description 73
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
- A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
- A61K47/48515—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups
- A61K47/48569—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups the antibody being targeting a determinant of a tumour cell
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3095752B2 (en) | Second generation monoclonal antibodies with binding specificity for TAG-72 and human carcinoma and methods of using the same | |
| EP0220858B1 (en) | Monoclonal anti-human breast cancer antibodies, corresponding hybridomas, the production and use thereof | |
| US5153118A (en) | Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens and methods for employing the same | |
| CA1339607C (en) | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients | |
| US5688657A (en) | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor | |
| JP2660241B2 (en) | Monoclonal antibody | |
| AU661816B2 (en) | Urinary tumor associated antigen, antigenic subunits uses and methods of detection | |
| Vessella et al. | Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens | |
| Starling et al. | Human prostate tissue antigens defined by murine monoclonal antibodies | |
| Ware et al. | Production of monoclonal antibody αPro3 recognizing a human prostatic carcinoma antigen | |
| JP2574269B2 (en) | Monoclonal antibodies having binding specificity for human prostate tumor associated antigen and methods of using them | |
| EP0282581A1 (en) | Monoclonal paratopic molecule directed to human ganglioside gd2 | |
| AU612973B2 (en) | Methods and compositions relating to regression-associated antigens | |
| JP2919961B2 (en) | Monoclonal antibodies and their use for antigen differentiation of squamous cell carcinoma | |
| CA2222551A1 (en) | Tumor associated epitopes | |
| EP0424107A1 (en) | A novel tumor-associated antigen | |
| CN109593131A (en) | A kind of anti-14-3-3 η protein monoclonal antibody and application thereof | |
| AU625856B2 (en) | Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same | |
| STEIN et al. | A murine monoclonal antibody raised against human non-small cell carcinoma of the lung | |
| Sikora et al. | Monoclonal antibodies | |
| JPH02500405A (en) | Monoclonal paratopic molecule against human ganglioside GD2 |